ClinicalTrials.gg
CompletedNCT04727580Updated Nov 25, 2024

HSK7653 in Chinese Patients with Impaired Glucose Tolerance

A Phase 2 interventional study of HSK7653 10mg Q2W and HSK7653 25mg Q2W in Impaired Glucose Tolerance, sponsored by Haisco Pharmaceutical Group Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-11-25.

Sponsored by Haisco Pharmaceutical Group Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 24 studies in Glucose Intolerance with a site in China — 9 open to participants now, 10 under way, none of them phase 3. Glucose Intolerance · China.

Enrollment
17th of 21
99 · median 150
Started
2021
the only one that year
Phase 2
2 of 24
1 open now
Registered
11th of 24
by date
Lead sponsor
1 of 24
Haisco Pharmaceutical Group Co., Ltd.

Among the 24 studies in Glucose Intolerance with a site in China, this one is the 17th largest by enrollment of the 21 interventional ones that give a count, is the only one that started in 2021, is one of 2 in phase 2, and was the 11th registered.

Glucose Intolerance

793 studies on the registry are indexed under Glucose Intolerance; 115 are open to participants now.

Browse Glucose Intolerance studies →

Open to participants now

9 of the 24 studies in Glucose Intolerance with a site in China are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 70 Glucose Intolerance studies recruiting now, 14 (20%) set no upper age limit and 51 (73%) stop at 75 or younger; 10 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Glucose Intolerance with a site in China, or all of them as a file.
02

Study summary

This study is being done to evaluate the efficacy, safety of HSK7653 in chinese participants with impaired glucose tolerance.

03

Conditions studied

  • Impaired Glucose Tolerance

Keywords

  • Impaired Glucose Tolerance
  • DPP-4 inhibitor
  • Prediabetes
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Impaired glucose tolerance;
  • (Body Mass Index) in the range of ≥ 18.0 kg/m2 to ≤ 35.0 kg/m2 at screening;

Exclusion criteria

Exclusion Criteria:

  • History of diabetes mellitus;
  • History of severe endocrine disease, uncured cancer, acute pancreatitis prior to ;
  • Current uncontrolled hypertension, serious nephropathy prior to informed consent;
  • Serious Heart Failure (class III-IV of the functional classification), serious Arrhythmia, and Stroke within 6 months prior to informed consent;
  • Serious gastrointestinal disease within 2 weeks prior to informed consent;
  • Serious infection, trauma, and surgery within 3 months prior to informed consent;
  • History of treatment with Glucagon-like peptide 1(GLP-1) analogues, Dipeptidyl-Peptidase 4(DPP-IV) inhibitor;
  • Treatment with drugs that affect glucose metabolism within 8 weeks prior to informed consent;
  • (HGB) \< 10.0 g/dL(100 g/L);
  • Alcohol abuse within 6 months or drug abuse history within 5 years prior to informed consent;
  • Active infectious diseases;
  • Participation in another trial with an drug or instrument within 3 months prior to informed consent;
  • Women who are nursing or pregnant, or subjects with birth plans;
  • Other protocol-defined inclusion/exclusion criteria.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    HSK7653 10 mg

    Drug: HSK7653 10mg Q2W

  • Experimental
    HSK7653 25 mg

    Drug: HSK7653 25mg Q2W

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • HSK7653 5mg (2 tablets) and placebo of HSK7653 25mg (1 tablet) Q2W, oral, Day1 to week12

  • HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

  • DrugPlacebo

    Placebo of HSK7653 25mg (1 tablet) and placebo of HSK7653 5mg (2 tablets) Q2W, oral, Day1 to week12

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Plasma Glucose AUC 0-3h for Meal Tolerance Test (MTT) at Week 12

    Plasma glucose AUC 0-3 hours for MTT was measured at Baseline (Week 0) and at Week 12. After fasting for ≥8 hours, blood samples for glucose measurement were drawn at 0 minutes (at standard meal loading), 30 minutes, 60 minutes, 90 minutes, 120 minutes, and 180 minutes. At Week 12, participants received study drug or placebo 50 minutes prior to consuming a standard meal.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in Insulin AUC 0-3h for Meal Tolerance Test (MTT) at Week 12

    Time frame: Baseline and Week 12

  2. Change From Baseline in C-peptide AUC 0-3h for Meal Tolerance Test (MTT) at Week 12

    Time frame: Baseline and Week 12

  3. Change From Baseline in Fasting Glucose at Week 12

    Time frame: Baseline and Week 12

  4. Change From Baseline in Fasting Insulin at Week 12

    Time frame: Baseline and Week 12

  5. Change From Baseline in Fasting C-peptide at Week 12

    Time frame: Baseline and Week 12

  6. Change From Baseline in HOMA-IS at Week 12

    Time frame: Baseline and Week 12

  7. Change From Baseline in HOMA-β at Week 12

    Time frame: Baseline and Week 12

  8. Change From Baseline in Hemoglobin A1c (HbA1c) at Week 12

    Time frame: Baseline and Week 12

  9. Change From Baseline in Plasma Glucose Area Under the Curve 0 to 3 Hours (AUC 0-3 Hrs) for Oral Glucose Tolerance Test (OGTT) at Week 10

    Time frame: Baseline and Week 10

  10. Incidence of Treatment-Emergent Adverse Events

    Time frame: Baseline and Week 12

07

Study locations

1 site
  • Emergency General Hospital
    Beijing, Beijing 100028, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Jun 2022, 14 months.

Of 22 phase 2 interventional studies under Glucose Intolerance, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 99. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2021
First posted
Jan 27, 2021
StartActual
Mar 29, 2021
Primary completionActual
Jun 12, 2022
CompletionActual
Jun 29, 2022
Last update
Nov 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04727580
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Mar 29, 2021
Primary completion
Jun 12, 2022
Completion
Jun 29, 2022
Last update
Nov 25, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HSK7653

Start the discussion